Tiziana announces positive clinical data from a secondary progressive multiple sclerosis patient treated for six months with intranasally administered foralumab, a fully human anti-cd3 monoclonal antibody

New york, march 10, 2022 (globe newswire) -- tiziana life sciences (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today reported positive clinical data in a patient with secondary progressive multiple sclerosis (spms), following completion of six months of treatment with intranasally administered foralumab, at the brigham and women's hospital (bwh), harvard university, boston, ma. in addition to being well-tolerated, both biological and clinical improvements were seen in this patient using tiziana's novel immunotherapy technology, which, importantly overcame the challenge of delivering this antibody across the blood-brain barrier to affect immunomodulation in the brain.
TLSA Ratings Summary
TLSA Quant Ranking